Aeterna Zentaris Inc (AEZS)

2.700 0.000 (0.00%)
Closed CAD Disclaimer

Aeterna Zentaris Inc Company Profile

Sector
Healthcare
Employees
12
Equity Type
ORD
Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as oncology indications; and AEZS-150, a delayed clearance parathyroid hormonefusion polypeptide that is in preclinical trail for the treatment of hypoparathyroidism in adults. Aeterna Zentaris Inc. has a license agreement with University of Wuerzburg to research, develop, manufacture, and sell a potential COVID-19 vaccine; development, manufacture, and commercialization of the treatment for neuromyelitis optica spectrum disorder; and for pre-clinical development towards the potential treatment of Parkinson’s disease. It also has a license agreement with Consilient Health Ltd. and NK MEDITECH Ltd. for the development and commercialization of macimorelin in the Republic of Korea; a distribution and commercialization agreement with Er-Kim Pharmaceuticals Bulgaria EOOD for the commercialization of macimorelin for the diagnosis of growth hormone deficiency in children and adults in Turkey and some non-European Union Balkan countries; as well as The University of Sheffield, the United Kingdom for the research, development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of primary hypoparathyroidism. Aeterna Zentaris Inc. was incorporated in 1990 and is headquartered in Summerville, South Carolina.
Contact Information
Address
Summerville,29486 United States
Phone
843 900 3223
Fax
-
Top Executives
Name
Age
Since
Title
René Frydman 0 0000 Member of the Scientific Advisory Board
Klaus H. R. Diedrich 0 0000 Member of the Scientific Advisory Board
Marcel Verheij 0 0000 Member of the Scientific Advisory Board
Gerald Batist 0 0000 Member of the Scientific Advisory Board
Daniel Douglas Von Hoff 75 2005 Member of the Scientific Advisory Board
Carolyn S. Egbert 0 2012 Independent Chair of the Board
Ulf R. Rapp 0 0000 Member of the Scientific Advisory Board
Dennis Turpin 0 1999 Independent Director
Klaus Paulini 0 2019 President, CEO & Executive Director
Peter G. Edwards 62 2020 Independent Director
Gilles R. Gagnon 69 2007 Independent Director
Hartmut Michel 0 0000 Member of the Scientific Advisory Board
Alan H. DeCherney 0 0000 Member of the Scientific Advisory Board
Frans M. J. Debruyne 0 0000 Member of the Scientific Advisory Board
Clear All
0Selected
Please try another search

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.